Genetic and Biotechnological Approaches to Gestational Diabetes Mellitus: Advancing Diagnostics, Treatment Strategies, and Public Health Implications

Background Gestational diabetes mellitus (GDM) is a disorder where pregnant women have difficulty processing glucose, which influences the mother's and the fetus's health. The rising prevalence of GDM, often linked to obesity, highlights the need to study its processes and develop appropriate treatment techniques. Conventional diagnostic approaches may not accurately anticipate or address genetic predispositions, emphasizing the need for further investigation. Objective This study aims to explore genetic and biotechnological approaches to improve diagnostics, treatment, and public health strategies for GDM. Methodology This research was carried out in two hospitals in Pakistan over a period of 12 months, from January to December 2023. A sample size of 260 was determined using an anticipated GDM prevalence of 15%. The data were obtained by administering structured questionnaires, doing anthropometric measures, and analyzing blood samples for genetic information. The statistical study included the use of descriptive statistics, chi-square tests, and logistic regression to examine the relationships between genetic markers and the risk of GDM. The significance level of these associations was assessed using a p-value of <0.05. Results Among the 260 individuals with GDM included in the research, 52 (20.00%) and 73 (28.08%) patients had the TCF7L2 risk variation. The study found that the TCF7L2 and FTO risk polymorphisms were linked to a higher likelihood of developing GDM among the participants. The association was statistically significant, with p-values of 0.012 and 0.045, respectively. Logistic regression analysis showed that the TCF7L2 risk variant had an odds ratio of 2.35 (95% confidence interval [CI]: 1.21-4.56, p = 0.012), while the FTO risk variant had an odds ratio of 1.97 (95% CI: 1.05-3.70, p = 0.045). There is a substantial association between consuming a large amount of sugar (OR: 2.10, 95% CI: 1.15-3.82, p = 0.017) and engaging in little physical activity (OR: 1.85, 95% CI: 1.07-3.22, p = 0.025) and an increased risk of GDM. Treatment brought the glucose levels of people with GDM down to normal in 68.49% of cases. Conclusion Integrating genetic screening for TCF7L2 and FTO variants with lifestyle modifications may enhance early detection and personalized management of GDM, leading to improved maternal and fetal health outcomes.